Miproxifene: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Selective estrogen receptor modulator}} | |||
{{Drugbox | {{Drugbox | ||
| | | verifiedfields = changed | ||
| verifiedrevid = 477002123 | |||
| verifiedrevid = | | IUPAC_name = 1-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-3-(dimethylamino)propan-2-ol | ||
| IUPAC_name = 4-[( | | image = Miproxifene.png | ||
| image = Miproxifene. | | width = 200px | ||
| width = | | CAS_number = 129912-70-1 | ||
| PubChem = 3033965 | |||
| ChemSpiderID = 2298535 | |||
| UNII = 0X9U0Q2R8K | |||
| KEGG = D05082 | |||
| ChEMBL = 2104010 | |||
| C=25 | |||
| H=29 | |||
| N=1 | |||
| O=2 | |||
| smiles = CC/C(=C(/c1ccc(OCC(CN(C)C)O)cc1)\c2ccccc2)c3ccccc3 | |||
}} | |||
'''Miproxifene''' is a [[selective estrogen receptor modulator]] (SERM) that has been studied for its potential use in the treatment of [[breast cancer]]. It is a derivative of [[tamoxifen]], a well-known SERM used in the treatment and prevention of breast cancer. | |||
==Mechanism of Action== | |||
Miproxifene functions by binding to [[estrogen receptors]] in the body, particularly those found in breast tissue. By doing so, it can block the effects of estrogen, a hormone that can promote the growth of certain types of breast cancer cells. This mechanism is similar to that of other SERMs, which can act as estrogen antagonists in some tissues while acting as agonists in others. | |||
==Pharmacology== | |||
Miproxifene is designed to have a more favorable profile compared to tamoxifen, with the aim of reducing side effects and improving efficacy. The drug's structure allows it to selectively modulate estrogen receptor activity, potentially offering benefits in terms of reduced risk of [[endometrial cancer]] and other estrogen-related side effects. | |||
==Clinical Development== | |||
Miproxifene has been the subject of various clinical trials to assess its safety and efficacy in the treatment of breast cancer. These studies have focused on its ability to reduce tumor size and prevent the progression of the disease. However, as of the latest updates, miproxifene has not been approved for clinical use and remains an investigational drug. | |||
==Potential Benefits== | |||
The potential benefits of miproxifene include its ability to act as an effective anti-estrogen agent in breast tissue while minimizing adverse effects in other tissues. This selectivity could make it a valuable option for patients who are at risk of developing breast cancer or who have already been diagnosed with the disease. | |||
== | ==Side Effects== | ||
As with other SERMs, miproxifene may cause side effects, although its specific profile is still under investigation. Common side effects associated with SERMs include hot flashes, vaginal discharge, and an increased risk of thromboembolic events. The development of miproxifene aims to mitigate these risks while providing effective treatment. | |||
==Related Pages== | |||
* [[Tamoxifen]] | |||
* [[Selective estrogen receptor modulator]] | |||
* [[Breast cancer]] | |||
* [[Estrogen receptor]] | |||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
[[Category: | [[Category:Experimental cancer drugs]] | ||
Revision as of 19:11, 22 March 2025
Selective estrogen receptor modulator
| Miproxifene | |
|---|---|
| File:Miproxifene.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 129912-70-1 |
| PubChem | 3033965 |
| DrugBank | |
| ChemSpider | 2298535 |
| KEGG | D05082 |
Miproxifene is a selective estrogen receptor modulator (SERM) that has been studied for its potential use in the treatment of breast cancer. It is a derivative of tamoxifen, a well-known SERM used in the treatment and prevention of breast cancer.
Mechanism of Action
Miproxifene functions by binding to estrogen receptors in the body, particularly those found in breast tissue. By doing so, it can block the effects of estrogen, a hormone that can promote the growth of certain types of breast cancer cells. This mechanism is similar to that of other SERMs, which can act as estrogen antagonists in some tissues while acting as agonists in others.
Pharmacology
Miproxifene is designed to have a more favorable profile compared to tamoxifen, with the aim of reducing side effects and improving efficacy. The drug's structure allows it to selectively modulate estrogen receptor activity, potentially offering benefits in terms of reduced risk of endometrial cancer and other estrogen-related side effects.
Clinical Development
Miproxifene has been the subject of various clinical trials to assess its safety and efficacy in the treatment of breast cancer. These studies have focused on its ability to reduce tumor size and prevent the progression of the disease. However, as of the latest updates, miproxifene has not been approved for clinical use and remains an investigational drug.
Potential Benefits
The potential benefits of miproxifene include its ability to act as an effective anti-estrogen agent in breast tissue while minimizing adverse effects in other tissues. This selectivity could make it a valuable option for patients who are at risk of developing breast cancer or who have already been diagnosed with the disease.
Side Effects
As with other SERMs, miproxifene may cause side effects, although its specific profile is still under investigation. Common side effects associated with SERMs include hot flashes, vaginal discharge, and an increased risk of thromboembolic events. The development of miproxifene aims to mitigate these risks while providing effective treatment.
